You are here: Industry Insights > Market News > South Africa asks SII to take back one million doses of COVID-19 vaccine: Reports

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

TAYACN Drying Ammonium thiocyanate ZLG series vibration fluidized bed dryer

TAYACN Drying Nickel chloride water ZLG series vibration fluidized bed dryer

TAYACN Drying Flavoring ZLG series vibration fluidized bed dryer

TAYACN Drying Resin ZLG series vibration fluidized bed dryer

TAYACN Drying Thiourea particles ZLG series vibration fluidized bed dryer

TAYACN Drying Sodium percarbonate ZLG series vibration fluidized bed dryer

South Africa asks SII to take back one million doses of COVID-19 vaccine: Reports

expresspharmaFebruary 18, 2021

Tag: South Africa , COVID-19 Vaccine , 501Y.V2 , SII

Favorites

South Africa has asked the Serum Institute of India to take back one million doses of COVID-19 vaccine that the company had sent in early February, as per a report in The Economic Times.

The company did not immediately respond to a Reuters request for comment.

South Africa’s health minister had informed last week that the government could sell AstraZeneca’s vaccine after the country halted its rollout following a small clinical trial that showed it offered minimal protection against mild to moderate illness from the 501Y.V2 coronavirus variant.

Previous:Glenmark launches SUTIB (Sunitinib) capsules in India to treat kidney cancer

Next:Research reveals Pfizer-BioNTech COVID-19 vaccine elicits strong immune response with single dose

Alzheimer’s Disease: Charting the Course from Plaques to Promise

Muhammad Farhan KhalidMay 28, 2025

New Tools，New Hope，New Frontier

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

PharmaSourcesMay 16, 2025

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

PR NewswireMay 12, 2025

South Africa asks SII to take back one million doses of COVID-19 vaccine: Reports | Pharmasources.com

Illuccix China Phase 3 Study Completes Enrolment

PR NewswireMay 13, 2025

Telix Pharmaceuticals Limited announces that the pivotal Phase 3 registration study of TLX591-CDx for prostate cancer imaging in Chinese patients has completed patient enrolment.

free性video西欧极品,伊人依成久久人综合网,中文字幕人妻一区二区三区熟女,男女高潮激烈无遮挡免费观软件 ,成人3d动漫一区二区三区

South Africa asks SII to take back one million doses of COVID-19 vaccine: Reports

Related News

Alzheimer’s Disease: Charting the Course from Plaques to Promise

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

Illuccix China Phase 3 Study Completes Enrolment

You may like
More>>

free性video西欧极品,伊人依成久久人综合网,中文字幕人妻一区二区三区熟女,男女高潮激烈无遮挡免费观软件 ,成人3d动漫一区二区三区

South Africa asks SII to take back one million doses of COVID-19 vaccine: Reports

Related News

Alzheimer’s Disease: Charting the Course from Plaques to Promise

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

Illuccix China Phase 3 Study Completes Enrolment

You may likeMore>>

You may like
More>>